niacin has been researched along with Hyperlipoproteinemias in 34 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess effects of niacin on risk factors of atherosclerosis in men with coronary heart disease (CHD) and high lipoprotein(a) [Lp(a)] levels." | 5.15 | [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels]. ( Afanas'eva, MI; Afanas'eva, OI; Ezhov, MV; Liakishev, AA; Pokrovskiĭ, SN; Safarova, MS; Tripoten', MI; Trukhacheva, EP, 2011) |
| "A total of 98 patients selected and classified into type IIa and IIb hyperlipoproteinemia according to Fredrickson and Lees (1965) were pre-treated for 6 months with a commercially available combination product (containing clofibrate and nicotinic acid)." | 5.05 | [Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug]. ( Steger, W, 1980) |
| "To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia." | 3.69 | Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. ( Chretien, SD; Gray, DR; Kashyap, ML; Morgan, T, 1994) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Prophylactic treatment of the hyperlipoproteinemia with the drugs niceritrol (Perycit) and beta-pyridylcarbinol (Ronicol) significantly reduced the elevated plasma cholesterol level and reduced the degree of atherosclerosis in the abdominal aorta and the coronary arteries." | 1.27 | [Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs]. ( Jacobsson, L, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (44.12) | 18.7374 |
| 1990's | 12 (35.29) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 6 (17.65) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hafiane, A | 1 |
| Kellett, S | 1 |
| Genest, J | 1 |
| Zsíros, N | 1 |
| Paragh, G | 1 |
| Harangi, M | 1 |
| Shin, HJ | 1 |
| McCullough, PA | 1 |
| Artemeva, NV | 1 |
| Safarova, MS | 2 |
| Ezhov, MV | 2 |
| Afanasieva, OI | 1 |
| Dmitrieva, OA | 1 |
| Pokrovsky, SN | 1 |
| Klose, G | 1 |
| Trukhacheva, EP | 1 |
| Afanas'eva, OI | 1 |
| Afanas'eva, MI | 1 |
| Tripoten', MI | 1 |
| Liakishev, AA | 1 |
| Pokrovskiĭ, SN | 1 |
| SCHOEN, H | 1 |
| ZELLER, W | 1 |
| HENNING, N | 1 |
| Leithäuser, B | 1 |
| Gerk, U | 1 |
| Mrowietz, C | 1 |
| Jung, F | 1 |
| Park, JW | 1 |
| Odetti, P | 1 |
| Cheli, V | 1 |
| Carta, G | 1 |
| Maiello, M | 1 |
| Viviani, GL | 1 |
| Hanefeld, M | 1 |
| Hora, C | 1 |
| Schulze, J | 1 |
| Rothe, G | 1 |
| Barthel, U | 1 |
| Haller, H | 1 |
| Saunders, RN | 1 |
| Azarnoff, DL | 1 |
| Steger, W | 1 |
| Gray, DR | 1 |
| Morgan, T | 1 |
| Chretien, SD | 1 |
| Kashyap, ML | 1 |
| Rodriguez, CR | 1 |
| Seman, LJ | 1 |
| Ordovas, JM | 1 |
| Jenner, J | 1 |
| Genest, MS | 1 |
| Wilson, PW | 1 |
| Schaefer, EJ | 2 |
| Zhao, XQ | 1 |
| Brown, BG | 1 |
| Hillger, L | 1 |
| Sacco, D | 1 |
| Bisson, B | 1 |
| Fisher, L | 1 |
| Albers, JJ | 1 |
| Otto, C | 1 |
| Schwandt, P | 1 |
| Scanu, AM | 1 |
| Lepre, F | 1 |
| Campbell, B | 1 |
| Crane, S | 1 |
| Hickman, P | 1 |
| Dalmau Serra, J | 1 |
| Vogt, HB | 1 |
| Drood, JM | 1 |
| Zimetbaum, PJ | 1 |
| Frishman, WH | 1 |
| Hunninghake, DB | 1 |
| Olsson, AG | 2 |
| Ruhn, G | 1 |
| Erikson, U | 1 |
| Wahlberg, G | 2 |
| Walldius, G | 2 |
| Kirstein, P | 1 |
| Romics, L | 1 |
| Davignon, J | 1 |
| Blum, CB | 1 |
| Levy, RI | 2 |
| Jacobsson, L | 1 |
| Stuyt, PM | 1 |
| Chanu, B | 1 |
| Parker, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population[NCT02515747] | 1,400 participants (Actual) | Interventional | 1993-01-31 | Completed | |||
| Familial Atherosclerosis Treatment Study[NCT00000512] | Phase 3 | 146 participants (Actual) | Interventional | 1984-01-31 | Completed | ||
| Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940] | Phase 3 | 120 participants (Actual) | Interventional | 2018-05-28 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for niacin and Hyperlipoproteinemias
| Article | Year |
|---|---|
Treatment options for low high-density lipoproteins.
Topics: Atherosclerosis; Biomarkers; Cholesterol Ester Transfer Proteins; Diabetes Mellitus, Type 2; Diabeti | 2014 |
[Clinical significance of and treatment options for increased lipoprotein(a)].
Topics: Aspirin; Biomarkers; Blood Component Removal; Cardiovascular Diseases; Carrier Proteins; Cholesterol | 2014 |
Focus on lipids: high-density lipoprotein cholesterol and its associated lipoproteins in cardiac and renal disease.
Topics: Amides; Apolipoprotein A-I; Benzodiazepines; Black or African American; Cholesterol Ester Transfer P | 2014 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
[When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination].
Topics: Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Ni | 1999 |
Hyperlipoproteinemias: part IV. Drug regimens.
Topics: Anticholesteremic Agents; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Niacin; Probucol | 1991 |
Nicotinic acid for the treatment of hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Coronary Disease; Drug Therapy, Combination; Humans; Hyperlipoproteinemia | 1991 |
Drug treatment of dyslipoproteinemia.
Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; | 1990 |
[Basic principles of drug therapy of hyperlipoproteinemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol; Clofibrate; Humans; Hyperlipoproteinemias; Hypolipidem | 1988 |
Pathogenesis and management of lipoprotein disorders.
Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom | 1985 |
7 trials available for niacin and Hyperlipoproteinemias
| Article | Year |
|---|---|
Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
Topics: Adult; Apoprotein(a); Biomarkers; Down-Regulation; Humans; Hyperlipoproteinemias; Hypolipidemic Agen | 2015 |
[Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Atherosclerosis; Atorvastatin; Carotid Arteries; Cor | 2011 |
Effect of nicotinic acid associated with retinol and tocopherols on plasma lipids in hyperlipoproteinaemic patients.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Com | 1984 |
Current status of drugs used to treat hyperlipoproteinemias.
Topics: Aminosalicylic Acid; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Enzyme Induction; H | 1982 |
[Therapy of lipoproteinemia. Comparison between Lipo-Merz retard and a commercial combination drug].
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Drug Combinations | 1980 |
Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
Topics: Adult; Apolipoproteins B; Colestipol; Coronary Disease; Coronary Vessels; Double-Blind Method; Exerc | 1993 |
Low-dose sustained release nicotinic acid (Tri-B3) and lipoprotein (a)
Topics: Delayed-Action Preparations; Humans; Hyperlipoproteinemias; Lipoprotein(a); Lipoproteins; Niacin | 1992 |
17 other studies available for niacin and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Optimal lipid treatment: possibilities and current limitations].
Topics: Anion Exchange Resins; Anticholesteremic Agents; Blood Component Removal; Cardiovascular Diseases; C | 2011 |
[STUDIES ON THE TREATMENT OF ENDOGENOUS HYPERLIPOPROTEINEMIA WITH BETA-PYRIDYL-CARBINOL].
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Lipoproteins; Methanol; Niacin | 1963 |
Influence of xantinole nicotinic acid on cutaneous microcirculation in patients with coronary artery disease and hyperlipoproteinemia.
Topics: Aged; Blood Pressure; Capillaries; Coronary Artery Disease; Female; Heart Rate; Humans; Hyperlipopro | 2008 |
Reduced incidence of cardiovascular complications and mortality in hyperlipoproteinemia (HLP) with effective lipid correction. The Dresden HLP study.
Topics: Adolescent; Adult; Cerebrovascular Disorders; Cholesterol; Cholestyramine Resin; Clofibrate; Combine | 1984 |
Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans.
Topics: Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoprotei | 1994 |
Lipoprotein(a) and coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apolipoproteins; Apoprotein(a); Child; Coronary Disease; | 1994 |
Lp(a): a link between thrombosis and atherosclerosis.
Topics: Adult; Arteriosclerosis; Child; Fatty Acids, Omega-3; Humans; Hyperlipoproteinemias; Hypolipidemic A | 1992 |
[Drug therapy of hyperlipoproteinemias].
Topics: Adolescent; Child; Child, Preschool; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglut | 1991 |
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
Topics: Adult; Analysis of Variance; Arteriosclerosis; Blood Pressure; Cholesterol, VLDL; Combined Modality | 1990 |
Effects of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Humans; Hyperlipoprotein | 1990 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Rational drug therapy of the hyperlipoproteinemias, Part II.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human | 1986 |
[Experimental hyperlipoproteinemia and arteriosclerosis in minipigs--effect of various drugs].
Topics: Animals; Arteries; Arteriosclerosis; Cholesterol; Hypercholesterolemia; Hyperlipoproteinemias; Hypol | 1986 |
[Drugs in hyperlipidemia].
Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi | 1987 |
[Drug treatment of hyperlipoproteinemia].
Topics: Anticholesteremic Agents; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Niacin | 1987 |
Xanthomas and hyperlipidemias.
Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr | 1985 |
Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis.
Topics: Animals; Apolipoproteins; Arteriosclerosis; Bile Acids and Salts; Carbohydrate Metabolism; Cholester | 1985 |